Axsome Therapeutics AXSM Balance Sheet Statement
| FY'25 | FY'24 | FY'23 | FY'22 | ||
|---|---|---|---|---|---|
| $322.93M+2.4% | $315.35M-18.3% | $386.19M+92.3% | $200.84M+132% | ||
| $224.46M+58.1% | $142M+49.8% | $94.82M+152% | $37.7M— | ||
| $27.94M+77.6% | $15.73M+3.9% | $15.14M+250% | $4.32M— | ||
| $588.99M+21.4% | $485.06M-3.8% | $504.26M+105% | $245.64M+184% | ||
| $562K-3.8% | $584K-31.0% | $846K+17.2% | $722K+154% | ||
| $12.04M0.0% | $12.04M0.0% | $12.04M+16.8% | $10.31M— | ||
| $40.52M-13.6% | $46.89M-12.0% | $53.29M-10.7% | $59.66M— | ||
| $689.81M+21.3% | $568.5M-3.4% | $588.24M+77.5% | $331.48M+278% | ||
| $65.54M-9.0% | $72M+77.0% | $40.68M+5.4% | $38.61M+194% | ||
| $70M— | $0— | —— | —— | ||
| $378.84M+64.6% | $230.1M+65.7% | $138.85M+43.8% | $96.56M+319% | ||
| $117.75M-34.8% | $180.71M+1.5% | $178.07M+88.9% | $94.26M+92.0% | ||
| $601.51M+17.6% | $511.48M+28.8% | $397.26M+79.0% | $221.92M+208% | ||
| $5K0.0% | $5K0.0% | $5K+25.0% | $4K+5.8% | ||
| -$1.31B-16.3% | -$1.12B-34.4% | -$835.57M-40.1% | -$596.33M-45.7% | ||
| $88.3M+54.9% | $57.02M-70.1% | $190.98M+74.3% | $109.56M+601% | ||
| $689.81M+21.3% | $568.5M-3.4% | $588.24M+77.5% | $331.48M+278% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- What are Axsome Therapeutics's total assets?
- Axsome Therapeutics (AXSM) holds $713.6M in total assets, up 19.6% year over year.
- How much debt does Axsome Therapeutics have?
- Axsome Therapeutics carries $219.9M in total debt against $54.6M of shareholders' equity, a debt-to-equity ratio of 4.03.
- How much cash does Axsome Therapeutics have?
- Axsome Therapeutics holds $305.1M in cash and equivalents.
- Can Axsome Therapeutics cover its short-term obligations?
- Its current ratio is 1.39 — current assets exceed current liabilities.
- Where does Axsome Therapeutics's balance sheet data come from?
- Every line is extracted from Axsome Therapeutics's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
